Opiant Pharmaceuticals Inc (NASDAQ:OPNT) CFO David D. O’toole purchased 1,000 shares of the stock in a transaction dated Tuesday, August 13th. The shares were acquired at an average price of $15.46 per share, with a total value of $15,460.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
OPNT opened at $14.62 on Friday. The stock’s 50-day moving average price is $13.11 and its 200 day moving average price is $13.13. Opiant Pharmaceuticals Inc has a 12-month low of $9.98 and a 12-month high of $29.55. The firm has a market cap of $64.25 million, a price-to-earnings ratio of -2.06 and a beta of 0.43.
Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its earnings results on Thursday, August 8th. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.86. Opiant Pharmaceuticals had a negative return on equity of 12.74% and a negative net margin of 11.78%. The firm had revenue of $6.78 million for the quarter, compared to analyst estimates of $3.91 million. On average, research analysts anticipate that Opiant Pharmaceuticals Inc will post 0.4 earnings per share for the current year.
A number of research firms have recently weighed in on OPNT. Northland Securities reiterated a “buy” rating on shares of Opiant Pharmaceuticals in a report on Friday, August 2nd. ValuEngine raised Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 6th.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Advisor Group Inc. lifted its stake in Opiant Pharmaceuticals by 57.2% during the 4th quarter. Advisor Group Inc. now owns 4,700 shares of the technology company’s stock worth $69,000 after acquiring an additional 1,710 shares in the last quarter. BlackRock Inc. lifted its stake in Opiant Pharmaceuticals by 44.0% during the 4th quarter. BlackRock Inc. now owns 10,259 shares of the technology company’s stock worth $149,000 after acquiring an additional 3,137 shares in the last quarter. Northern Trust Corp raised its position in Opiant Pharmaceuticals by 3.5% in the 4th quarter. Northern Trust Corp now owns 41,803 shares of the technology company’s stock valued at $604,000 after purchasing an additional 1,398 shares in the last quarter. Spark Investment Management LLC raised its position in Opiant Pharmaceuticals by 17.6% in the 1st quarter. Spark Investment Management LLC now owns 15,100 shares of the technology company’s stock valued at $198,000 after purchasing an additional 2,265 shares in the last quarter. Finally, Granite Investment Partners LLC acquired a new stake in Opiant Pharmaceuticals in the 1st quarter valued at about $356,000. 18.60% of the stock is currently owned by hedge funds and other institutional investors.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Read More: Liquidity
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.